Key Points
- CFO Kory James Wentworth sold 11,388 shares on March 10 at an average price of $13.02 for about $148,272, leaving him with 121,510 shares (an 8.57% reduction); he also sold 5,089 and 7,988 shares on March 9 and March 4 respectively.
- Shares traded down ~2.3% to $13.18 (market cap ≈ $504.65M) and analysts hold a "Moderate Buy" consensus with a $18.50 price target; the company beat EPS estimates (-$0.94 vs. -$1.32) but reported weak revenue of $1.3M versus a $7.41M estimate.
Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) COO Nathan Dowden sold 3,116 shares of Entrada Therapeutics stock in a transaction on Monday, March 9th. The shares were sold at an average price of $13.02, for a total value of $40,570.32. Following the completion of the transaction, the chief operating officer owned 210,482 shares of the company's stock, valued at approximately $2,740,475.64. The trade was a 1.46% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Entrada Therapeutics Price Performance
Shares of TRDA stock traded down $1.01 during trading hours on Thursday, hitting $12.49. 38,897 shares of the company's stock were exchanged, compared to its average volume of 232,028. The stock's 50-day moving average is $11.23 and its 200-day moving average is $8.86. The stock has a market cap of $478.19 million, a price-to-earnings ratio of -3.62 and a beta of -0.12. Entrada Therapeutics, Inc. has a 52 week low of $4.93 and a 52 week high of $13.65.
Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last announced its earnings results on Thursday, February 26th. The company reported ($0.94) earnings per share for the quarter, beating analysts' consensus estimates of ($1.32) by $0.38. Entrada Therapeutics had a negative return on equity of 39.83% and a negative net margin of 565.48%.The company had revenue of $1.30 million during the quarter, compared to analyst estimates of $7.41 million. Equities research analysts forecast that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current fiscal year.
Institutional Trading of Entrada Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. State of Wyoming lifted its position in Entrada Therapeutics by 130.9% during the 2nd quarter. State of Wyoming now owns 7,575 shares of the company's stock valued at $51,000 after purchasing an additional 4,295 shares during the period. Russell Investments Group Ltd. grew its position in shares of Entrada Therapeutics by 72.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company's stock worth $51,000 after buying an additional 3,707 shares during the period. Occudo Quantitative Strategies LP acquired a new stake in shares of Entrada Therapeutics during the 2nd quarter worth approximately $68,000. IHT Wealth Management LLC bought a new stake in shares of Entrada Therapeutics during the second quarter worth approximately $72,000. Finally, AXQ Capital LP bought a new stake in shares of Entrada Therapeutics during the third quarter worth approximately $67,000. 86.39% of the stock is owned by institutional investors.
Analysts Set New Price Targets
A number of brokerages have weighed in on TRDA. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Entrada Therapeutics in a research note on Monday, December 29th. Wall Street Zen raised shares of Entrada Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, February 28th. HC Wainwright reissued a "buy" rating and issued a $20.00 price target on shares of Entrada Therapeutics in a report on Wednesday, February 18th. Oppenheimer began coverage on shares of Entrada Therapeutics in a research report on Wednesday, January 28th. They issued an "outperform" rating and a $21.00 price objective for the company. Finally, Guggenheim raised Entrada Therapeutics to a "strong-buy" rating in a report on Wednesday, February 11th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Entrada Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $18.50.
Read Our Latest Research Report on Entrada Therapeutics
About Entrada Therapeutics
(
Get Free Report)
Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.
The company's pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
